Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor

Changhoon Yoo(Ulsan College), Baek‐Yeol Ryoo(Asan Medical Center), Yong Sang Hong(Ulsan College), Kyu‐pyo Kim(Ulsan College), Seung‐Mo Hong(Ulsan College), Song Cheol Kim(Ulsan College), Min‐Hee Ryu(Ulsan College), Hyungwoo Cho(Ulsan College), Tae Won Kim(Asan Medical Center), Heejung Chae(Ulsan College), Yoon‐Koo Kang(Ulsan College), Heung-Moon Chang(Asan Medical Center), Min Jeong Song(Ulsan College)

Cancer Chemotherapy and Pharmacology

December 10, 2016

10.1007/s00280-016-3215-3

Cited by 32

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

|Science Translational Medicine|2014|5.1k

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

|Science|2008|4k

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

|Journal of Clinical Oncology|2019|1.8k

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

|New England Journal of Medicine|2019|1.5k